medigraphic.com
ISSN 1727-897X (Electronic)

2020, Number 5

<< Back Next >>

Medisur 2020; 18 (5)

A current look at myasthenia gravis

Milanés AAR, Molina CK, Pino MJ, Milanés MM, Ojeda LÁM

Language: Spanish
References: 31
Page: 907-918
PDF size: 145.43 Kb.


ABSTRACT

Myasthenia gravis is a rare, autoimmune chronic disease whose prevalence has increased since the 1980s due to improved diagnosis and increased longevity of the population. The objective of this work is to update the most important aspects of the entity, a knowledge that all health personnel and students must have. For this, a total of 32 bibliographic references resulting from searches in virtual libraries were consulted: Scopus, Google Academic and Medline. It was concluded that, from the improvement in the knowledge of the pathophysiology of the disease, the diagnosis and the treatment, it has been possible to reduce mortality, improve the quality of life of patients and their functionality.


REFERENCES

  1. Herrera Lorenzo O, Infante Ferrer J, Casares Albernas F, Varela Hernández A. Miastenia gravis: diagnóstico y tratamiento. AMC [revista en Internet]. 2009 [citado 5 Jun 2019];13(5):[aprox. 9p]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-02552009000500014.

  2. Pascuzzi RM. The history of myasthenia gravis. Neurol Clin N Am. 1994;12:231-42.

  3. Godoy DA, Jardim M, Massotti L, Di Napoli M. The myasthenic patient in crisis: an update of the management in Neurointensive Care Unit. Arq Neuro-Psiquiatr. 2013;71(9- A):627-39.

  4. Gómez S, Álvarez Y, Puerto J. Miastenia gravis: una visión actual de la enfermedad. MéD UIS. 2013;26(3):13-22.

  5. Sánchez Sánchez JG, Pérez Padilla CA. Análisis de caso sobre miastenia gravis de predominio ocular [Tesis]. Ambato: Universidad Técnica de Ambato; 2016.

  6. Harrison TR. Trastornos neurológicos. En: Harrison´Principios de Medicina Interna. New York: McGraw-Hill Interamericana; 2006. p. 678-83.

  7. Arosemena Coronel M. Miastenia gravis de presentación bulbar. Reporte de caso y revisión bibliográfica. Rev Ecuat Neurol [revista en Internet]. 2017 [citado 6 May 2019];26(3):[aprox. 8p]. Disponible en: http://scielo.senescyt.gob.ec/scielo.php?script=sci_arttext&pid=S2631-25812017000200289.

  8. Nazar CA, Araneda AS, Morgado A, Salgado C. Miastenia gravis ocular: Caracterización de una serie de pacientes. Rev Ciencias Médicas [revista en Internet]. 2019 [citado 5 Ene 2020];44(3):[aprox. 7p]. Disponible en: https://www.researchgate.net/publication/336214148_Miastenia_gravis_ocular_caracterizacion_de_una_serie_de_pacientes.

  9. González L, Riquelme VA, Fuentealba SM, Canales ZJ, Fuentes EA, Saldìas FR, et al. Results of extended transesternal thymectomy for Myasthenia Gravis: Experience with 58 patients. Rev Med Chile. 2018;146:460-9.

  10. Gilhus NE, Nacu A, Andersen JB, Owie JF. Myasthenia gravis and risks for comorbility. Eur J Neurol. 2015;22(1):17-23.

  11. Binck S, Vicent A, Palace J. Myasthenia Gravis: a clinical- inmunological update. J Neurol. 2016;263(4):826-34.

  12. Silvestri N, Wolfe G. Myasthenia gravis. Semin Neurol. 2012;32(3):215-26.

  13. Thiruppathi M, Rowin J, Li Jiang Q, Sheng JR, Prabhakar BS, Meriggioli MN. Functional defect in regulatory T cells in myasthenia gravis. Ann N Y Acad Sci. 2012;1274:68-76.

  14. Gradolatto A, Nazzal D, Foti M, Bismuth J, Truffault F, Le Panse R, et al. Defects of immunoregulatory mechanisms in myasthenia gravis: role of IL-17. Ann N Y Acad Sci. 2012;1274:40-7.

  15. Cavalcante P, Cufi P, Mantegazza R, Berrih-Aknin S, Bernasconi P, Le Panse R. Etiology of myasthenia gravis: innate immunity signature in pathological thymus. Autoimmun Rev. 2013;12(9):863-74.

  16. Gómez A, Rodríguez J, Bayona H. Miastenia gravis [Internet]. Bogotá: Asociación Colombiana de Neurología; 2017 [citado 7 May 2020]. Disponible en: http://www.acnweb.org/guia/g1c07i.pdf.

  17. Montomoli C, Citterio A, Piccolo G, Cioccale R, Ferretti VV, Fratti C, et al. Epidemiology and geographical variation of myasthenia gravis in the province of Pavia, Italy. Neuroepidemiology. 2012;38(2):100-5.

  18. Martínez Torres S, Gómez Molinero I, Martínez Girón R. Puesta al día en la miastenia gravis. SEMERGEN. 2018;44(5):351-4.

  19. Statland JM, Ciafaloni E. Myasthenia gravis, five new things. Neurol Clin Pract. 2013;3(2):126-33.

  20. Grob D, Brunner N, Namba T. Evolución clínica de la miastenia gravis y el impacto de distintos factores y del tratamiento. Muscle Nerve. 2008;37:141-9.

  21. Asociación Brasileña de Miastenia. Protocolo Clínico e Diretrizes Terapêuticas [Internet]. Sao Paulo: ABRAMI; 2015 [citado 6 Abr 2020]. Disponible en: http://www.abrami.org.br/medicamentos/protocolo-clinico-e-diretrizes-terapeuticas.

  22. Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmune Dis. 2012;2012:874-80.

  23. Benatar M, Burns T, Swan AV. Serological, pharmacological and electrophysiological tests for the diagnosis of myasthenia gravis. Cochrane Database of Systematic Reviews. 2010;(12):1-10.

  24. Cherian A, Baheti NN, Iype T. Electrophysiological study in neuromuscular junction disorders. Ann Indian Acad Neurol. 2013;16(1):34-41.

  25. Sussan J, Farrugia ME, Maddinson P, Hill M, Leite MI, Hilton-Jones D. Myasthenia Gravis: Associations of Brithish Neurologists management guidelines. Pract Neurol. 2015;15:199-206.

  26. Sander DB, Wolfe GI, Benatar M, Evoli A, Gilhus Ne, Ila I, et al. Orientación consenso internacional para la gestión de la miastenia gravis. Neurologìa. 2016;87:419.

  27. Saeteng S, Tantraworasin A, Siwachat S, Lertprasertsuke N, Euathringchit J, Wannasopha Y. Preoperative plasmapheresis for elective thymectomy in myasthenia patient: is it necessary?. ISRN Neurol. 2013;2013:1-6.

  28. Li ZY. China guidelines for the diagnosis and treatment of myasthenia gravis. Neuroimmunology. 2015;15(3):199-206.

  29. Kumar R. Myasthenia Gravis and thymic Neoplasm brief review. World J Clin Cases. 2015;3(12):980-3.

  30. Wolge G, Kaminski H, Aban I, Minisman G, Kuo H, Marx A, et al. Rabdomized trial of thymectomy in myasthenia gravis. (Correction from: N Engl J Med. 2017; 376:2097). Engl J Med. 2016;375:511-22.

  31. Zalazar GJ, Diaconchuk MA, Martínez CM, Wettstein LG, Millessi ES. Crisis miasténica: ¿Predispone la demora en el diagnóstico o el error diagnóstico a su aparición? Neurología Argentina. 2017;9(4):243-46.




2020     |     www.medigraphic.com